SCHEMBL6630352

SCHEMBL6630352

CCCCC(O)c1ccccc1F

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.42
LMNA P02545 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
CYP3A4 P08684 2/20 0.41
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
KDM4E B2RXH2 1/20 0.41
PPARG P37231 2/20 0.40
HDAC3 O15379 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PDE2A O00408 1/20 0.38
TAS1R3 Q7RTX0 1/20 0.37
TAS1R1 Q7RTX1 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
IDO1 P14902 1/20 0.37
TDO2 P48775 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4910363 0.94 PPARG (0.45) ALDH1A1LMNAMEN1KMT2ANPSR1
SCHEMBL30557985 0.94 PPARG (0.45) ALDH1A1LMNAMEN1KMT2ANPSR1
SCHEMBL26326732 0.93 PPARG (0.47) ALDH1A1LMNAMEN1KMT2ANPSR1
SCHEMBL1913425 0.90 CES2 (0.42) ALDH1A1LMNAMEN1KMT2ANPSR1
SCHEMBL8216569 0.86 ALDH1A1 (0.46) ALDH1A1LMNACYP3A4KDM4EPPARG
SCHEMBL7786189 0.85 CES2 (0.44) ALDH1A1LMNAMEN1KMT2ANPSR1
SCHEMBL21605359 0.84 ALDH1A1 (0.36) ALDH1A1LMNAMEN1KMT2ANPSR1
SCHEMBL11994152 0.82 CYP19A1 (0.43) ALDH1A1LMNAMEN1KMT2ANPSR1
SCHEMBL7983483 0.82 PDE2A (0.53) LMNACYP3A4CES2CES1PDE2A
SCHEMBL29669152 0.82 PDE2A (0.53) LMNACYP3A4CES2CES1PDE2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040204417-A1 Novel benzothienyl or indole derivatives, preparation and use thereof as inhibitors of prenyl transferase proteins PIERRE FABRE MEDICAMENT (FR) 2004-10-14 US disclosed
EP-1395581-A2 NOVEL BENZOTHIENYL OR INDOLE DERIVATIVES, PREPARATION AND USE THEREOF AS INHIBITORS OF PRENYL TRANSFERASE PROTEINS PIERRE FABRE MEDICAMENT (FR) 2004-03-10 EP disclosed
WO-2002098852-A2 NOVEL BENZOTHIENYL OR INDOLE DERIVATIVES, AND USE THEREOF AS INHIBITORS OF PRENYL TRANSFERASE PROTEINS PIERRE FABRE MEDICAMENT (FR) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204417-A1 Novel benzothienyl or indole derivatives, preparation and use thereof as inhibitors of prenyl transferase proteins CBR1, CBR3, HCCS ALDH1A1 2558/4885LMNA 2717/4885MEN1 4758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.